South Korea-based SN BioScience announced on Thursday that it has entered into a domestic manufacturing technology transfer and co-development contract with Boryeong, a pharmaceutical company in Korea, for the albumin nanoparticle anticancer drug (code name: SNA-001), a generic version of Abraxane.
SNA-001 has been developed by SN BioScience for the first time in Korea and the fourth time in the world. It is a product that electrostatically binds cytotoxic anticancer drugs to albumin utilising albumin present in human blood as a drug carrier. Abraxane is a global blockbuster first developed by Abraxis BioScience Inc (acquired by Celgene who became a subsidiary of BMS), with sales of USD1.5bn worldwide in 2020.
The contract allows Boryeong to have exclusive manufacturing and distribution rights in Korea for SNA-001. SN BioScience is to receive milestones and double-digit royalties based on the development stage.
Mikart adds Fette double-sided tablet presses
Biocon Biologics enters five-year partnership with Sandoz Australia
Mallinckrodt names new directors
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition